Targeting serine synthesis pathway to reverse paclitaxel resistance in NSCLC with combination of paclitaxel and anlotinib
Collectively, our study demonstrates that anlotinib combined with PTX, via SSP inhibition, is a promising strategy for overcoming PTX resistance in NSCLC.
Authors
- Wen Zhu (ORCID: https://orcid.org/0000-0002-7118-2791)
- Yanyun Hong
- Pengwu Zheng
- Mengting Yu
- Shan Xu
- Yingxing He
- Qiaoli Lv
- Qingshan Pan
Institutions
- Jiangxi Science and Technology Normal University (CN)
- Jiangxi Provincial Cancer Hospital (CN)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2026-01-05
- DOI
- https://doi.org/10.1186/s13046-025-03627-w
- Primary Topic
- Cancer, Hypoxia, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00